Alcor Scientific v. Alifax Holding: Federal Circuit Splits Decision on ISED Analyzer Patents
Alcor Scientific and inventor Francesco Frappa pursued infringement claims against Alifax Holding and Sire Analytical Systems over three patents covering ISED blood sedimentation analyzer technology. The Federal Circuit issued a split ruling — affirming some claims, reversing others, and remanding — after 777 days of appellate proceedings.
A three-patent ISED analyzer dispute earns a split Federal Circuit verdict
Filed on 26 April 2022, Case No. 22-1723 brought Alcor Scientific, Inc. and inventor Francesco A. Frappa before the Federal Circuit to challenge a lower court’s resolution of an infringement action against Alifax Holding Spa and Sire Analytical Systems SRL. The dispute centres on three U.S. patents — US6272533, US7005107B2, and US6632679B1 — all directed at ISED (Infra-red Scanning Erythrocyte Deformability) analyzer technology used in automated blood sedimentation rate testing.
The Federal Circuit issued a nuanced ruling on 11 June 2024, affirming the lower court in part, reversing in part, and remanding the case for further proceedings. This split disposition means that Alcor and Frappa prevailed on at least some of their appellate arguments, while Alifax and Sire retained victories on others. The remand requires the district court to revisit specific issues where the Federal Circuit found reversible error — the precise scope of those issues is not fully detailed in the public docket record.
A duration of 777 days is consistent with complex multi-patent appeals at the Federal Circuit, particularly those involving technical claim construction disputes in specialised diagnostic instruments. The mixed outcome suggests neither party achieved a clean sweep, which typically indicates contested claim construction or damages questions. What specific claims or issues drove each portion of the ruling remains subject to the full opinion’s analysis, which practitioners should review for claim-level guidance.
Filing to Case Remanded in 777 days
777 days at the Federal Circuit — above the median for mixed-outcome patent appeals
Federal Circuit splits decision: what affirmed-in-part, reversed-in-part means
What ‘Affirmed-in-Part, Reversed-in-Part, Remanded’ means
A split Federal Circuit disposition means the appellate court found no reversible error on some issues (affirmed) but identified reversible error on others (reversed). Remand sends those reversed issues back to the lower court for further proceedings consistent with the Federal Circuit’s guidance. No single party achieved a complete victory — the lower court’s judgment survives in part and is overturned in part.
Mixed appellate outcomeAlcor and Frappa: a partial appellate win keeps claims alive
For Alcor Scientific and inventor Frappa, the reversal-in-part is a meaningful outcome — it signals the Federal Circuit found at least one legal or factual error below that favoured the defendants. The remand opens a second opportunity to pursue those reversed issues before the district court. However, the affirmed portions mean some adverse findings from the lower court stand, limiting the overall scope of the win.
Partial plaintiff recoveryAlifax and Sire retain partial wins but face remand exposure
Alifax Holding and Sire Analytical Systems preserved some lower-court victories through the affirmed portions of the ruling. However, the reversal-in-part means those defendants must now re-litigate at least some issues before the district court. The remand creates renewed litigation risk and cost exposure for the defendants on the issues where the Federal Circuit found the lower court erred in their favour.
Partial defendant exposure on remandISED analyzer IP landscape remains unsettled after mixed ruling
For competitors and manufacturers in the automated blood sedimentation diagnostics space, this split ruling signals that the enforceability and scope of Alcor’s three ISED analyzer patents remain actively contested. The remand introduces continued uncertainty around freedom-to-operate for products that may overlap with US6272533, US7005107B2, or US6632679B1. Companies active in this diagnostic segment should monitor the district court remand proceedings closely.
FTO uncertainty persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Alcor Scientific, Inc. | Company | Medical diagnostics IP holder — asserting US6272533, US7005107B2, and US6632679B1Search in Eureka ↗ |
| Co-Plaintiff | Alcor Scientific, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Francesco A. Frappa | Individual | Search in Eureka ↗ |
| Defendant | Alifax Holding Spa | Individual | Alifax Holding Spa — Italian diagnostics manufacturer, maker of ISED analyzer systemsSearch in Eureka ↗ |
| Co-Defendant | Sire Analytical Systems SRL | Company | Search in Eureka ↗ |
| Defendant counsel | Michael Daly | Attorney | Counsel for Alifax Holding SpaSearch in Eureka ↗ |
| Defendant law firm | Barton Gilman LLP | Law Firm | Representing Alifax Holding SpaSearch in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The Federal Circuit’s ‘Affirmed-in-Part, Reversed-in-Part and Remanded’ disposition is among the most consequential mixed outcomes in patent appeals — it confirms that the lower court’s analysis was correct on certain issues but legally flawed on others. Under Federal Circuit review standards, claim construction receives de novo review while factual findings are assessed for clear error. The remand instruction signals that at least one issue requires fresh adjudication below, and the precise scope of what was reversed will be determinative for both parties’ litigation posture going forward.
US6272533, US7005107B2 & US6632679B1 — ISED blood sedimentation analyzer technology
The three patents at issue — US6272533, US7005107B2, and US6632679B1 — are directed at ISED (Infra-red Scanning Erythrocyte Deformability) technology, a method of measuring erythrocyte sedimentation rate (ESR) and red blood cell characteristics using infrared scanning rather than conventional Westergren tube methods. Filed across application numbers US09/250277, US10/641644, and US09/501118, the patents represent a family of innovations covering the core analytical method, apparatus, and system components. ESR measurement is a standard clinical diagnostic test used to detect inflammation and a range of medical conditions.
Alcor Scientific’s three-patent portfolio on ISED technology creates overlapping coverage across method, apparatus, and system claims — a prosecution strategy that is typically designed to close design-around pathways for competitors. Alifax Holding and Sire Analytical Systems are European diagnostics manufacturers active in automated ESR analysis, making them direct competitive threats in this space. The outcome of this Federal Circuit appeal — and the pending remand — will materially shape who can manufacture and distribute ISED-type analyzers in the U.S. market without infringement exposure.
Should your ISED or automated ESR analyzer product be cleared against these patents?
Any company developing, manufacturing, importing, or distributing automated blood sedimentation rate analyzers that use infrared or optical scanning methodologies should treat US6272533, US7005107B2, and US6632679B1 as active FTO risks. The Federal Circuit’s partial reversal and remand means enforceability questions are not yet fully resolved — but the affirmed portions confirm that at least some claims survived appellate scrutiny. Diagnostic instrument OEMs, contract manufacturers, and U.S. distributors of European ESR products are particularly exposed.
PatSnap Eureka’s FTO Search Agent can map each of Alcor’s three patents against your product’s technical specifications, identifying independent claim elements that may overlap with your analyzer’s scanning method, sample handling, or measurement algorithms. Eureka also tracks the remand proceedings in real time, alerting your team to any district court rulings that shift the enforceability landscape — so your FTO analysis stays current as this litigation evolves.
Run a freedom-to-operate analysis on US6272533 to assess your product’s exposure
Run FTO in Eureka →Similar Federal Circuit patent appeals in medical diagnostics instruments
Cases involving multi-patent infringement appeals at the Federal Circuit in the automated diagnostic instruments sector, with claim construction and remand issues.
What this case signals for the medical diagnostics IP landscape
A split Federal Circuit ruling on diagnostic instrument patents creates ripple effects across the automated blood analysis sector.
Multi-patent ISED cases invite claim construction scrutiny at the Federal Circuit
When an appeal involves three related diagnostic patents, the Federal Circuit often splits outcomes across different claim terms or patent families. This case is consistent with that pattern — practitioners prosecuting or licensing ISED or blood sedimentation IP should anticipate granular claim-by-claim analysis on appeal, not portfolio-level resolutions.
Remand proceedings reset the litigation clock — monitor district court closely
The remand to district court means litigation over the reversed issues is far from over. Companies whose products touch ISED analyzer technology should track the remand proceedings, as any district court ruling on damages, infringement scope, or claim validity will directly affect the FTO landscape for this patent family.
Alcor v Alifax — key questions answered
The Federal Circuit issued a mixed ruling in Case No. 22-1723 on 11 June 2024: affirmed-in-part, reversed-in-part, and remanded. This means the lower court’s decision was upheld on some issues, reversed on others, and the case was sent back to the district court for further proceedings on the reversed issues. Neither party achieved a complete appellate victory.
Three U.S. patents were asserted: US6272533 (application US09/250277), US7005107B2 (application US10/641644), and US6632679B1 (application US09/501118). All three are directed at ISED (Infra-red Scanning Erythrocyte Deformability) analyzer technology for automated blood sedimentation rate measurement.
The ISED analyzer was the product at issue. ISED systems use infrared scanning technology to measure erythrocyte sedimentation rate (ESR) and red blood cell characteristics. Alifax Holding Spa and Sire Analytical Systems SRL were accused of infringing Alcor Scientific’s patents covering this technology.
Remand means the Federal Circuit has sent the reversed issues back to the lower district court for further adjudication consistent with the appellate court’s guidance. This is not a final resolution — the district court must now re-examine the issues on which the Federal Circuit found reversible error, which may result in additional trial proceedings, damages recalculation, or further claim analysis.
Yes. The affirmed portions of the Federal Circuit ruling confirm that some claims survived appellate review, meaning US6272533, US7005107B2, and US6632679B1 remain active enforcement risks. The pending remand proceedings may further define claim scope. Companies in the automated ESR analyzer space should conduct a current FTO analysis and monitor the district court remand for any rulings affecting enforceability.
PatSnap Eureka searches patents and litigation data to answer instantly.